Cargando…
Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial
AIMS AND OBJECTIVES: The aim was to evaluate the comparative efficacy and safety of escitalopram versus desvenlafaxine in postmenopausal women with depression and anxiety in our study cohort. MATERIALS AND METHODS: A randomized, open-label, intention-to-treat, comparative study was conducted over a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767953/ https://www.ncbi.nlm.nih.gov/pubmed/31579188 http://dx.doi.org/10.4103/jmh.JMH_139_18 |
_version_ | 1783455025391992832 |
---|---|
author | Mahajan, Sonia Shinde Tandon, Vishal R. Arora, Manu Mahajan, Annil Kotwal, Suman |
author_facet | Mahajan, Sonia Shinde Tandon, Vishal R. Arora, Manu Mahajan, Annil Kotwal, Suman |
author_sort | Mahajan, Sonia Shinde |
collection | PubMed |
description | AIMS AND OBJECTIVES: The aim was to evaluate the comparative efficacy and safety of escitalopram versus desvenlafaxine in postmenopausal women with depression and anxiety in our study cohort. MATERIALS AND METHODS: A randomized, open-label, intention-to-treat, comparative study was conducted over a period of 1 year. Group 1 (n = 20) patients received tablet escitalopram 10 mg once daily orally which was increased to 20 mg/day when needed at the first follow-up. Group 2 (n = 20) patients received tablet desvenlafaxine 50 mg once daily orally which was increased to 100 mg/day when needed at the first follow-up. Patients were followed at 3 and 6 weeks. Primary endpoints were change in baseline scores (recorded as mean ± standard deviation) of Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A), and safety was also assessed and compared. RESULTS: Forty patients completed the study. Escitalopram was statistically better than desvenlafaxine in reducing depression after 6 weeks of treatment (P < 0.05). Both the drugs were found to be equally effective in treating anxiety. Furthermore, they showed comparable safety and tolerability. CONCLUSION: Escitalopram appears to be more effective on short-term basis in treating depression, and both the drugs appear equally effective in combating anxiety. Furthermore, they appear to be equally safe and well tolerated in postmenopausal women with depression and anxiety. |
format | Online Article Text |
id | pubmed-6767953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-67679532019-10-02 Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial Mahajan, Sonia Shinde Tandon, Vishal R. Arora, Manu Mahajan, Annil Kotwal, Suman J Midlife Health Original Article AIMS AND OBJECTIVES: The aim was to evaluate the comparative efficacy and safety of escitalopram versus desvenlafaxine in postmenopausal women with depression and anxiety in our study cohort. MATERIALS AND METHODS: A randomized, open-label, intention-to-treat, comparative study was conducted over a period of 1 year. Group 1 (n = 20) patients received tablet escitalopram 10 mg once daily orally which was increased to 20 mg/day when needed at the first follow-up. Group 2 (n = 20) patients received tablet desvenlafaxine 50 mg once daily orally which was increased to 100 mg/day when needed at the first follow-up. Patients were followed at 3 and 6 weeks. Primary endpoints were change in baseline scores (recorded as mean ± standard deviation) of Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A), and safety was also assessed and compared. RESULTS: Forty patients completed the study. Escitalopram was statistically better than desvenlafaxine in reducing depression after 6 weeks of treatment (P < 0.05). Both the drugs were found to be equally effective in treating anxiety. Furthermore, they showed comparable safety and tolerability. CONCLUSION: Escitalopram appears to be more effective on short-term basis in treating depression, and both the drugs appear equally effective in combating anxiety. Furthermore, they appear to be equally safe and well tolerated in postmenopausal women with depression and anxiety. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6767953/ /pubmed/31579188 http://dx.doi.org/10.4103/jmh.JMH_139_18 Text en Copyright: © 2019 Journal of Mid-life Health http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Mahajan, Sonia Shinde Tandon, Vishal R. Arora, Manu Mahajan, Annil Kotwal, Suman Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial |
title | Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial |
title_full | Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial |
title_fullStr | Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial |
title_full_unstemmed | Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial |
title_short | Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial |
title_sort | comparative efficacy and safety of escitalopram versus desvenlafaxine in postmenopausal women with depression and anxiety: a randomized, open-label, comparative trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767953/ https://www.ncbi.nlm.nih.gov/pubmed/31579188 http://dx.doi.org/10.4103/jmh.JMH_139_18 |
work_keys_str_mv | AT mahajansoniashinde comparativeefficacyandsafetyofescitalopramversusdesvenlafaxineinpostmenopausalwomenwithdepressionandanxietyarandomizedopenlabelcomparativetrial AT tandonvishalr comparativeefficacyandsafetyofescitalopramversusdesvenlafaxineinpostmenopausalwomenwithdepressionandanxietyarandomizedopenlabelcomparativetrial AT aroramanu comparativeefficacyandsafetyofescitalopramversusdesvenlafaxineinpostmenopausalwomenwithdepressionandanxietyarandomizedopenlabelcomparativetrial AT mahajanannil comparativeefficacyandsafetyofescitalopramversusdesvenlafaxineinpostmenopausalwomenwithdepressionandanxietyarandomizedopenlabelcomparativetrial AT kotwalsuman comparativeefficacyandsafetyofescitalopramversusdesvenlafaxineinpostmenopausalwomenwithdepressionandanxietyarandomizedopenlabelcomparativetrial |